# Ocean Biomedical, Inc.: financial statements, quarterly

OCEA · OTC · CIK 1869974 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ocea.md) · [Financials](/companies/ocea/financials.md) · [Filings](/companies/ocea/filings.md) · [Insiders](/companies/ocea/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ocea/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [3.2](/filings/0001493152-24-014678.md) | [1.9](/filings/0001493152-24-014679.md) | [0.2 d](/filings/0001493152-24-047661.md) | [0.4](/filings/0001493152-24-051207.md) | [0.0](/filings/0001493152-24-051208.md) | [0.3](/filings/0001493152-25-001880.md) | [(0.0) d](/filings/0001641172-25-003155.md) | [0.0](/filings/0001641172-25-011080.md) | [0.0 d](/filings/0001493152-24-051208.md) | [0.0 d](/filings/0001493152-25-001880.md) | [0.0 d](/filings/0001641172-25-003155.md) | [0.0](/filings/0001641172-25-011080.md) |
| Operating income | $m | [(6.9)](/filings/0001493152-24-014678.md) | [(3.2)](/filings/0001493152-24-014679.md) | [(0.9) d](/filings/0001493152-24-047661.md) | [(5.4)](/filings/0001493152-24-051207.md) | [(2.8)](/filings/0001493152-24-051208.md) | [(2.7)](/filings/0001493152-25-001880.md) | [0.7 d](/filings/0001641172-25-003155.md) | [(0.6)](/filings/0001641172-25-011080.md) | [(0.7)](/filings/0001493152-24-051208.md) | [(0.8)](/filings/0001493152-25-001880.md) | [(1.8) d](/filings/0001641172-25-003155.md) | [(1.0)](/filings/0001641172-25-011080.md) |
| Interest expense | $m | not reported | not reported | not reported | [0.0](/filings/0001493152-24-051207.md) | [0.0](/filings/0001493152-24-014678.md) | [0.0](/filings/0001493152-24-014679.md) | [0.0 d](/filings/0001493152-24-047661.md) | [0.6](/filings/0001641172-25-011080.md) | not reported | not reported | not reported | [0.3](/filings/0001641172-25-011080.md) |
| Net income | $m | [(7.3)](/filings/0001493152-24-014678.md) | [(3.7)](/filings/0001493152-24-014679.md) | [(1.0) d](/filings/0001493152-24-047661.md) | [(72.1)](/filings/0001493152-24-051207.md) | [(11.4)](/filings/0001493152-24-051208.md) | [(14.1)](/filings/0001493152-25-001880.md) | [(16.9) d](/filings/0001641172-25-003155.md) | [13.0](/filings/0001641172-25-011080.md) | [(17.2)](/filings/0001493152-24-051208.md) | [(3.7)](/filings/0001641172-25-003155.md) | [(1.5) d](/filings/0001641172-25-003155.md) | [(8.2)](/filings/0001641172-25-011080.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001493152-24-014678.md) | [(0.16)](/filings/0001493152-24-014679.md) | not reported | [(2.90)](/filings/0001493152-24-051207.md) | [(0.43)](/filings/0001493152-24-051208.md) | [(0.53)](/filings/0001493152-25-001880.md) | not reported | [0.48](/filings/0001641172-25-011080.md) | [(0.63)](/filings/0001493152-24-051208.md) | [(0.13)](/filings/0001641172-25-003155.md) | not reported | [(0.09)](/filings/0001641172-25-011080.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001493152-24-014678.md) | [(0.16)](/filings/0001493152-24-014679.md) | not reported | [(2.90)](/filings/0001493152-24-051207.md) | [(0.43)](/filings/0001493152-24-051208.md) | [(0.53)](/filings/0001493152-25-001880.md) | not reported | [0.48](/filings/0001641172-25-011080.md) | [(0.63)](/filings/0001493152-24-051208.md) | [(0.13)](/filings/0001641172-25-003155.md) | not reported | [(0.09)](/filings/0001641172-25-011080.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.6](/filings/0001493152-22-019014.md) | [0.5](/filings/0001493152-22-028552.md) | [0.0](/filings/0001493152-24-047661.md) | [0.3](/filings/0001493152-24-014676.md) | not reported | [0.0](/filings/0001493152-24-014679.md) | [0.0](/filings/0001641172-25-003155.md) | [0.0](/filings/0001493152-24-051207.md) | [0.0](/filings/0001493152-24-051208.md) | not reported | not reported | not reported |
| Current assets | $m | [0.7](/filings/0001493152-22-019014.md) | [0.6](/filings/0001493152-22-028552.md) | [1.8](/filings/0001493152-24-047661.md) | [0.3](/filings/0001493152-24-014676.md) | [2.2](/filings/0001493152-24-014678.md) | [1.0](/filings/0001493152-24-014679.md) | [2.1](/filings/0001641172-25-003155.md) | [1.8](/filings/0001493152-24-051207.md) | [1.3](/filings/0001493152-24-051208.md) | [1.0](/filings/0001493152-25-001880.md) | [0.8](/filings/0001641172-25-011080.md) | [1.5](/filings/0001641172-25-011080.md) |
| Total assets | $m | [109](/filings/0001493152-22-019014.md) | [109](/filings/0001493152-22-028552.md) | [1.8](/filings/0001493152-24-047661.md) | [0.3](/filings/0001493152-24-014676.md) | [2.2](/filings/0001493152-24-014678.md) | [1.0](/filings/0001493152-24-014679.md) | [5.5](/filings/0001641172-25-003155.md) | [2.9](/filings/0001493152-24-051207.md) | [1.9](/filings/0001493152-24-051208.md) | [1.1](/filings/0001493152-25-001880.md) | [0.9](/filings/0001641172-25-011080.md) | [1.6](/filings/0001641172-25-011080.md) |
| Current liabilities | $m | [0.5](/filings/0001493152-22-019014.md) | [2.1](/filings/0001493152-22-028552.md) | [12.7](/filings/0001493152-24-047661.md) | [23.7](/filings/0001493152-24-014676.md) | [29.8](/filings/0001493152-24-014678.md) | [30.9](/filings/0001493152-24-014679.md) | [30.0](/filings/0001641172-25-003155.md) | [30.1](/filings/0001493152-24-051207.md) | [30.7](/filings/0001493152-24-051208.md) | [31.8](/filings/0001641172-25-003155.md) | [33.9](/filings/0001641172-25-011080.md) | [26.6](/filings/0001641172-25-011080.md) |
| Total liabilities | $m | [3.7](/filings/0001493152-22-019014.md) | [5.2](/filings/0001493152-22-028552.md) | [12.7](/filings/0001493152-24-047661.md) | [55.1](/filings/0001493152-24-014676.md) | [63.8](/filings/0001493152-24-014678.md) | [76.3](/filings/0001493152-24-014679.md) | [96.3](/filings/0001641172-25-003155.md) | [78.7](/filings/0001493152-24-051207.md) | [94.6](/filings/0001493152-24-051208.md) | [97.4](/filings/0001641172-25-003155.md) | [98.5](/filings/0001641172-25-011080.md) | [94.0](/filings/0001641172-25-011080.md) |
| Short-term borrowings | $m | not reported | not reported | [0.8](/filings/0001493152-24-014678.md) | not reported | [11.9](/filings/0001493152-24-014678.md) | not reported | [3.2](/filings/0001641172-25-003155.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(9.5)](/filings/0001493152-24-014679.md) | [(9.8)](/filings/0001493152-24-014679.md) | [(10.8)](/filings/0001641172-25-003155.md) | [(54.8)](/filings/0001493152-24-051208.md) | [(61.7)](/filings/0001493152-25-001880.md) | [(75.2)](/filings/0001493152-25-001880.md) | [(90.8)](/filings/0001641172-25-011080.md) | [(75.8)](/filings/0001641172-25-011080.md) | [(92.7)](/filings/0001493152-25-001880.md) | [(96.3)](/filings/0001641172-25-003155.md) | [(97.6)](/filings/0001641172-25-011080.md) | [(92.4)](/filings/0001641172-25-011080.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(151) d](/filings/0001493152-24-014678.md) | [(442) d](/filings/0001493152-24-014679.md) | [(33.0) d](/filings/0001493152-24-047661.md) | [(2,651)](/filings/0001493152-24-051207.md) | [(4,782) d](/filings/0001493152-24-051208.md) | [(1,130) d](/filings/0001493152-25-001880.md) | [(866) d](/filings/0001641172-25-003155.md) | [(485)](/filings/0001641172-25-011080.md) | [(290) d](/filings/0001493152-24-051208.md) | [(957) d](/filings/0001641172-25-003155.md) | [(2,448) d](/filings/0001641172-25-003155.md) | [(356)](/filings/0001641172-25-011080.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.4](/filings/0001493152-24-014676.md) | [23.4](/filings/0001493152-24-014678.md) | [23.4](/filings/0001493152-24-014679.md) | [24.8](/filings/0001493152-24-051207.md) | [26.5](/filings/0001493152-24-051208.md) | [26.6](/filings/0001493152-25-001880.md) | [27.3](/filings/0001641172-25-011080.md) | [27.5](/filings/0001493152-24-051208.md) | [27.5](/filings/0001493152-25-001880.md) | [91.0](/filings/0001641172-25-011080.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 232,365,143 at 2025-05-15, from the cover of the [10-Q filed 2025-05-15](/filings/0001641172-25-011080.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.